An International Observational Study of Adults With Acute Infection
NCT ID: NCT07069400
Last Updated: 2026-02-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
1500 participants
OBSERVATIONAL
2025-08-25
2027-06-08
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
International SARS-CoV-2 (COVID-19) Infection Observational Study
NCT04385251
Observational, Prospective Clinical Study to Evaluate Biomarkers as Indicators of Acute Bacterial or Viral Infections
NCT01917461
A COVID-19 Symptom, Exposure and Immune Response Registry
NCT04348942
COVID-19 Observational Research Collaboratory
NCT05394025
Cohort of the Specialist Network Infectious Diseases
NCT06879184
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Study group
The study population includes adult patients admitted to a hospital with a suspected or confirmed acute infection.
No intervention
This is an observational study
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
No intervention
This is an observational study
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Admitted to hospital (or in an emergency department with anticipated hospital admission) for the management of a suspected or confirmed acute infectious disease.
* Onset of symptoms of an infectious disease within the past 30 days.
* Informed consent for study participation by the participant or a surrogate decision maker if the participant lacks capacity for consent.
Exclusion Criteria
* Patient undergoing comfort care measures only such that treatment focuses on end- of-life symptom management over prolongation of life.
* Expected inability or unwillingness to participate in study procedures.
* In the opinion of the investigator, participation in the study is not in the best interest of the patient.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Minnesota
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Cavan Reilly, PhD
Role: PRINCIPAL_INVESTIGATOR
University of Minnesota
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Stanford University Hospital & Clinics (Site 203-003)
Palo Alto, California, United States
UCSF Medical Center (Site 203-001)
San Francisco, California, United States
University of Kansas Medical Center (Site 080-044)
Kansas City, Kansas, United States
University of Minnesota
Minneapolis, Minnesota, United States
Mount Sinai Medical Center (Site 301-012)
New York, New York, United States
Wake Forest Baptist Health (210-001)
Winston-Salem, North Carolina, United States
Cleveland Clinic Foundation (Site 207-001)
Cleveland, Ohio, United States
Vanderbilt University Medical Center (Site 212-001)
Nashville, Tennessee, United States
UT Southwestern Medical Center (084-001)
Dallas, Texas, United States
Intermountain Medical Center (Site 211-001)
Murray, Utah, United States
Hospital General de Agudos JM Ramos Mejia (Site 611-001)
Buenos Aires, , Argentina
St. Vincent's Hospital (612-002)
Sydney, New South Wales, Australia
Royal Brisbane and Women's Hospital (Site 612-055)
Brisbane, Queensland, Australia
CERMIPA (Site 403-001)
Abidjan, , Côte d’Ivoire
Rigshospitalet, CHIP (625-006)
Copenhagen, , Denmark
Evangelismos General Hospital (Site 635-020)
Athens, Attica, Greece
3rd Dept of Medicine, Medical School (Site 635-022)
Athens, Attica, Greece
Fujita Health University Hospital
Toyoake, Aichi-ken, Japan
Japan Institute for Health Security
Tokyo, , Japan
Tan Tock Seng Hospital
Singapore, , Singapore
Seoul National University Bundang Hospital
Seongnam-si, Gyeonggi-do, South Korea
Seoul St. Mary's Hospital
Seoul, , South Korea
Hospital Universitari Germans Trias i Pujol (Site 626-003)
Badalona, Barcelona, Spain
Chulalongkorn University and The HIV-NAT (Site 613-001)
Bangkok, , Thailand
MRC/UVRI & LSHTM Uganda Research Unit (Site 634-601)
Entebbe, , Uganda
Lira Regional Referral Hospital (Site 634-605)
Lira, , Uganda
Central City Clinical Hospital of Ivano-Frankivsk City Council (627-302)
Ivano-Frankivsk, , Ukraine
Royal Free Hospital (Site 634-006)
London, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
STRIVE 002
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.